NASDAQ · Drug Manufacturers - Specialty & Generic

Neoleukin Therapeutics, Inc. (NLTX) Stock

$3.49 +1.45% NASDAQ: NLTX Healthcare

Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused on developing immune-based treatments for conditions such as cancer, inflammatory responses, and autoimmune diseases, utilizing its proprietary protein design technology.

Valuation

MetricValue
Price$3.49
Market Cap$8.20M
P/E Ratio-11.26
P/B Ratio0.33
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$18.80
52-Week Low$3.42
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-37.88%
ROA-37.48%
ROCE-45.34%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.04
Current Ratio13.08

Annual Financials (USD)

Metric20202021202220242025
Revenue$0$0$0$0$0
Operating Profit$-34.0M$-61.0M$-59.0M$-83.0M$-103.0M
Net Profit$-33.0M$-61.0M$-58.0M$-75.0M$-90.0M
EPS$-3.20$-5.50$-5.07$-3.96$0.00
Op Margin-7478.5%-1011633.3%———

Balance Sheet (USD)

Metric20202021202220242025
Total Assets$211.0M$163.0M$116.0M$336.0M$289.0M
Total Liabilities$19.0M$20.0M$22.0M$25.0M$24.0M
Cash$193.0M$142.0M$38.0M$137.0M$104.0M
Borrowings$12.0M$13.0M$12.0M$12.0M$10.0M

Latest News

New Mideast fighting puts eurozone rate-setters on alert AFP · Jul 23, 2026 Dow Jones Futures Rise; Google, Tesla Fall On Earnings, Capex, But AI Stocks Climb Investor's Business Daily · Jul 23, 2026 What's the deal with peptides? The hyped market under US review AFP · Jul 23, 2026 TowneBank Reports Second Quarter 2026 Earnings GlobeNewswire · Jul 23, 2026 Pichai pushes back on claims Google is losing ground in AI race Reuters · Jul 23, 2026

Cash Flow (USD)

Metric20202021202220242025
Operating Cash Flow$-25.0M$-48.0M$-46.0M$-71.0M$-77.0M
Investing Cash Flow$-4.0M$-7.0M$-60.0M$-126.0M$13.0M
Financing Cash Flow$77.0M$1.0M$0$184.0M$31.0M
Net Cash Flow$50.0M$-50.0M$-105.0M$-12.0M$-33.0M
Free Cash Flow$-27.0M$-51.0M$-47.0M$-71.0M$-78.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.06
EV / EBITDA2.69
FCF Yield-1014.70%
Quick Ratio13.08
Interest Coverage-110758.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BIORBiora Therapeutics, Inc. $0.22 +0.00% 0.00 $994994 0.00%
CHROChannel Therapeutics Corporation $1.35 +7.14% -0.05 $8.90M 0.00%
CNTGCentogene N.V. $0.33 +100.00% -0.22 $9.42M 0.00%
CSCICOSCIENS Biopharma Inc. $2.72 +0.00% -0.35 $8.57M 0.00%
DMKPQDMK Pharmaceuticals Corporation $0.00 — 0.00 $1010 0.00%

About Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused on developing immune-based treatments for conditions such as cancer, inflammatory responses, and autoimmune diseases, utilizing its proprietary protein design technology. The company's leading investigational therapy is NL-201, a novel protein meticulously crafted to emulate the therapeutic effects of the IL-2/IL-15 cytokines. This product candidate is intended for the management of various malignancies, including renal cell carcinoma and melanoma. The organization, founded in 2003, was previously known as Aquinox Pharmaceuticals, Inc. before officially changing its name to Neoleukin Therapeutics, Inc. in August 2019. Its operations are based out of Seattle, Washington.

Neoleukin Therapeutics, Inc. is headquartered in US.

Neoleukin Therapeutics, Inc. (NLTX) stock trades at $3.49 with a market capitalization of $8.20M. The stock is valued at a price-to-earnings (P/E) ratio of -11.26, price-to-book of 0.33, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.42 and $18.80, and currently trades 81.4% below its 52-week high.

On profitability, Neoleukin Therapeutics, Inc. generates a return on equity (ROE) of -37.88%, return on capital employed of -45.34%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.neoleukin.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides